CN114761794A - 妊娠糖尿型病症的代谢谱筛查 - Google Patents

妊娠糖尿型病症的代谢谱筛查 Download PDF

Info

Publication number
CN114761794A
CN114761794A CN202080078823.XA CN202080078823A CN114761794A CN 114761794 A CN114761794 A CN 114761794A CN 202080078823 A CN202080078823 A CN 202080078823A CN 114761794 A CN114761794 A CN 114761794A
Authority
CN
China
Prior art keywords
subject
marker
test sample
metabolic
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080078823.XA
Other languages
English (en)
Chinese (zh)
Inventor
B·J·库斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN114761794A publication Critical patent/CN114761794A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202080078823.XA 2019-10-11 2020-10-09 妊娠糖尿型病症的代谢谱筛查 Pending CN114761794A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914294P 2019-10-11 2019-10-11
US62/914,294 2019-10-11
PCT/US2020/055020 WO2021072222A1 (en) 2019-10-11 2020-10-09 Metabolic profile screening for gestational diabetes

Publications (1)

Publication Number Publication Date
CN114761794A true CN114761794A (zh) 2022-07-15

Family

ID=75436783

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080078823.XA Pending CN114761794A (zh) 2019-10-11 2020-10-09 妊娠糖尿型病症的代谢谱筛查

Country Status (8)

Country Link
US (1) US20240085432A1 (https=)
EP (1) EP4022299A4 (https=)
JP (1) JP7607951B2 (https=)
KR (1) KR20220079582A (https=)
CN (1) CN114761794A (https=)
AU (1) AU2020361608A1 (https=)
CA (1) CA3157057A1 (https=)
WO (1) WO2021072222A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187381A (zh) * 2023-11-03 2023-12-08 南京医科大学 一种用于妊娠期糖尿病早期辅助诊断的甲基化区域标志物组合及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114167066B (zh) * 2022-01-24 2022-06-21 杭州凯莱谱精准医疗检测技术有限公司 生物标志物在制备妊娠糖尿病诊断试剂中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058142A2 (en) 2003-12-16 2005-06-30 Emory University Diabetes diagnostic
CA2690541A1 (en) * 2007-07-17 2009-01-29 Metabolon, Inc. Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same
WO2012058298A1 (en) * 2010-10-26 2012-05-03 Mayo Foundation For Medical Education And Research Biomarkers of reduced insulin action
EP3094968B1 (en) * 2014-01-15 2020-12-09 The Regents of The University of California Metabolic screening for gestational diabetes
JP2019027885A (ja) 2017-07-28 2019-02-21 国立大学法人千葉大学 妊娠糖尿病の発症リスクの診断用バイオマーカー
US20190310269A1 (en) * 2018-04-04 2019-10-10 Human Longevity, Inc. Systems and methods for measuring obesity using metabolome analysis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
贺佳 主编: "医学科研设计与统计分析", pages: 104 - 129 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187381A (zh) * 2023-11-03 2023-12-08 南京医科大学 一种用于妊娠期糖尿病早期辅助诊断的甲基化区域标志物组合及其应用
CN117187381B (zh) * 2023-11-03 2024-02-13 南京医科大学 一种用于妊娠期糖尿病早期辅助诊断的甲基化区域标志物组合及其应用

Also Published As

Publication number Publication date
AU2020361608A1 (en) 2022-04-21
EP4022299A4 (en) 2023-03-01
JP2022551656A (ja) 2022-12-12
KR20220079582A (ko) 2022-06-13
EP4022299A1 (en) 2022-07-06
WO2021072222A1 (en) 2021-04-15
US20240085432A1 (en) 2024-03-14
JP7607951B2 (ja) 2025-01-06
CA3157057A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
Koos et al. Early pregnancy metabolites predict gestational diabetes mellitus: implications for fetal programming
Rawal et al. A longitudinal study of thyroid markers across pregnancy and the risk of gestational diabetes
Horgan et al. Metabolic profiling uncovers a phenotypic signature of small for gestational age in early pregnancy
Caglar et al. Sex‐hormone‐binding globulin early in pregnancy for the prediction of severe gestational diabetes mellitus and related complications
Nguyen et al. Using proteomics to advance the search for potential biomarkers for preeclampsia: A systematic review and meta-analysis
Camunas-Soler et al. Predictive RNA profiles for early and very early spontaneous preterm birth
Anderson et al. Fetal hemoglobin, α1-microglobulin and hemopexin are potential predictive first trimester biomarkers for preeclampsia
Dockree et al. Pregnancy-specific reference intervals for C-reactive protein improve diagnostic accuracy for infection: a longitudinal study
AU2010240781A1 (en) Methods for determining maternal health risks
Kim et al. A protein microarray analysis of amniotic fluid proteins for the prediction of spontaneous preterm delivery in women with preterm premature rupture of membranes at 23 to 30 weeks of gestation
Yu et al. Changes of serum pentraxin-3 and hypersensitive CRP levels during pregnancy and their relationship with gestational diabetes mellitus
CN111094988A (zh) 先兆子痫生物标志物及相关系统和方法
US20240352527A1 (en) Methods and systems for determining a pregnancy-related state of a subject
Oğlak et al. The reduced serum concentrations of β-arrestin-1 and β-arrestin-2 in pregnancies complicated with gestational diabetes mellitus
Tamblyn et al. Serum and urine vitamin D metabolite analysis in early preeclampsia
Zorba et al. Visfatin serum levels are increased in women with preeclampsia: a case-control study
JP7607951B2 (ja) 妊娠性糖尿病に関する代謝プロファイルスクリーニング
Pugh et al. Does hypoglycemia following a glucose challenge test identify a high risk pregnancy?
Dan et al. Proteomic identification of biomarkers in maternal plasma that predict the outcome of rescue cerclage for cervical insufficiency
Swinburne et al. First‐trimester biomarkers of gestational diabetes mellitus: A scoping review
Pecks et al. A mass spectrometric multicenter study supports classification of preeclampsia as heterogeneous disorder
Takahashi et al. Early-pregnancy N-terminal pro-brain natriuretic peptide level is inversely associated with hypertensive disorders of pregnancy diagnosed after 35 weeks of gestation
Jiang et al. Integrative multi-omic analysis reveals potential biomarkers in the cervicovaginal fluid of patients with placenta accrete spectrum
Palanisamy et al. Transcriptomic analysis reveals potential biomarkers for early-onset pre-eclampsia using integrative bioinformatics and LASSO based approach
Šplíchal et al. Comparison of maternal omentin-1 levels and genetic variability between spontaneous term and preterm births

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination